Additional Holter and Telemetry Equipment Introduced

Posted:
7
January 2005

As demand for our QTc studies grows, we recently introduced new Holter and Telemetry equipment to enhance this crucial new service.When evaluating new medicines during early phase clinical trials, it is crucial that the impact on the cardiovascular system is monitored continuously. Furthermore, the demand for QTc studies has increased due to undesired side-effects of medicines that prolong cardiac repolarization such as pimozide, thioridazine and cisapride.Ambulatory Holter monitoring as well as continuous Telemetry ECG monitoring are the two new services that we provide at Richmond complementing our QTc Study set up.Our Holter monitors allow the recording of ambulatory ECGs over a continuous period up to 48 hours, whilst not disturbing the normal daily routine of our volunteers. In addition, using our Telemetry system, volunteers are monitored 24 hours a day, 7 days a week whilst in the research unit.Having a dedicated team of Research Physicians who, in conjunction with Cardiologists from the St George's Hospital Medical School, constantly monitor the volunteers enables immediate access to volunteer information and helping to speed analysis and any necessary action.At Richmond Pharmacology we are dedicated to the well being and safety of volunteers. We continue to make every effort acquiring the latest technology to provide our clients with excellent clinical trial services.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more